Number of the records: 1
Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines
- 1.
SYSNO ASEP 0520449 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Tick-borne encephalitis in Europe and Russia: Review of pathogenesis, clinical features, therapy, and vaccines Author(s) Růžek, Daniel (BC-A) RID, ORCID
Zupanc, T.A. (SI)
Borde, J. (DE)
Chrdle, A. (CZ)
Eyer, Luděk (BC-A) RID, ORCID
Karganova, G. (RU)
Kholodilov, I. (RU)
Knap, N. (SI)
Kozlovskaya, L. (RU)
Matveev, A. (RU)
Miller, A. D. (GB)
Osolodkin, D.I. (RU)
Överby, A.K. (SE)
Tikunova, N. V. (RU)
Tkachev, S. (RU)
Zajkowska, J. (PL)Number of authors 16 Source Title Antiviral Research. - : Elsevier - ISSN 0166-3542
Roč. 164, APR 2019 (2019), s. 23-51Number of pages 29 s. Publication form Print - P Language eng - English Country NL - Netherlands Keywords hepatitis-c-virus ; west-nile-virus ; 1st booster vaccination ; blood-brain-barrier ; antibody-dependent enhancement ; single nucleotide polymorphism ; amphipathic fusion inhibitor ; interferon-stimulated genes ; central-nervous-system ; long-term persistence ; Tick-borne encephalitis ; Tick-borne encephalitis virus ; Clinical course ; Antiviral therapy ; Vaccines ; Pathogenesis Subject RIV EE - Microbiology, Virology OECD category Microbiology R&D Projects NV16-34238A GA MZd - Ministry of Health (MZ) Method of publishing Limited access Institutional support BC-A - RVO:60077344 UT WOS 000463303700003 EID SCOPUS 85061389498 DOI 10.1016/j.antiviral.2019.01.014 Annotation Tick-borne encephalitis (TBE) is an illness caused by tick-borne encephalitis virus (TBEV) infection which is often limited to a febrile illness, but may lead to very aggressive downstream neurological manifestations. The disease is prevalent in forested areas of Europe and northeastern Asia, and is typically caused by infection involving one of three TBEV subtypes, namely the European (TBEV-Eu), the Siberian (TBEV-Sib), or the Far Eastern (TBEV-FE) subtypes. In addition to the three main TBEV subtypes, two other subtypes, i.e., the Baikalian (TBEV-Bkl) and the Himalayan subtype (TBEV-Him), have been described recently. In Europe, TBEV-Eu infection usually results in only mild TBE associated with a mortality rate of < 2%. TBEV-Sib infection also results in a generally mild TBE associated with a non-paralytic febrile form of encephalitis, although there is a tendency towards persistent TBE caused by chronic viral infection. TBE-FE infection is considered to induce the most severe forms of TBE. Importantly though, viral subtype is not the sole determinant of TBE severity, both mild and severe cases of TBE are in fact associated with infection by any of the subtypes. In keeping with this observation, the overall TBE mortality rate in Russia is similar to 2%, in spite of the fact that TBEV-Sib and TBEV-FE subtypes appear to be inducers of more severe TBE than TBEV-Eu. On the other hand, TBEV-Sib and TBEV-FE subtype infections in Russia are associated with essentially unique forms of TBE rarely seen elsewhere if at all, such as the hemorrhagic and chronic (progressive) forms of the disease. For post-exposure prophylaxis and TBE treatment in Russia and Kazakhstan, a specific anti-TBEV immunoglobulin is currently used with well-documented efficacy, but the use of specific TBEV immunoglobulins has been discontinued in Europe due to concerns regarding antibody-enhanced disease in naive individuals. Therefore, new treatments are essential. This review summarizes available data on the pathogenesis and clinical features of TBE, plus different vaccine preparations available in Europe and Russia. In addition, new treatment possibilities, including small molecule drugs and experimental immunotherapies are reviewed. The authors caution that their descriptions of approved or experimental therapies should not be considered to be recommendations for patient care. Workplace Biology Centre (since 2006) Contact Dana Hypšová, eje@eje.cz, Tel.: 387 775 214 Year of Publishing 2020 Electronic address https://www.sciencedirect.com/science/article/pii/S0166354218304479?via%3Dihub
Number of the records: 1